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Lipodystrophy syndromes have an estimated prevalence of 1.3–4.7 cases per million and as with other rare diseases conducting research can be challenging. The purpose of this review is to highlight recently published work that has provided important insights into the field of non-HIV associated lipodystrophy syndromes.
Recent findings: Lipodystrophies are a heterogenous group of disorders and as such research is often focused on specific subtypes of the condition. The identification of children affected by LMNA mutations provided insights into the natural history of FPLD2, specifically that the adipose tissue phenotype predates the onset of puberty.  Recent reports of heterozygous null variant carriers and the apparent absence of a lipodystrophy phenotype challenges our understanding of the molecular biology of perilipin 1 and its role in the pathogenesis of FPLD4. With a focus on therapeutics, studies delineating the differential responsiveness of PPAR gamma mutants to endogenous and synthetic ligands illustrated the potential for pharmacogenetics to inform therapeutic decisions in lipodystrophy due to PPARG mutations, while robust human studies have contributed important insights into the food independent metabolic effects of leptin in lipodystrophy.  Finally, rare syndromes of lipodystrophy continue to serve as an exemplar for the contribution of genetically determined adipose tissue expandability to metabolic disease in the general population.




Lipodystrophy syndromes are a group of disorders characterised by a selective deficiency in functional adipose tissue. Lipodystrophies are classified on the basis of whether they are genetic or acquired and within either subgroup the deficiency in adipose tissue can occur along a spectrum from the partial absence of adipose tissue in a particular region of the body to the near total absence of adipose tissue referred to as generalised lipodystrophy (1). Genetic forms of lipodystrophy range from the likely polygenic Köbberling syndrome (Familial partial lipodystrophy type 1) to monogenic disorders of lipodystrophy which may have an adipose tissue dominated phenotype as in the case of PPARG mutations or alternatively the lipodystrophy may exist as part of a more complex syndrome such as  Werner syndrome due to mutations in the RECQL2 gene (Table 1) (2,3). Acquired lipodystrophies represent the most common form of the condition largely contributed to by partial lipodystrophy related to anti-retroviral therapy although this is not associated with the severity of metabolic complications observed with other rarer forms of lipodystrophy(Table 2) (4,5). Many acquired lipodystrophies co-exist with autoimmune conditions and have been associated with disorders of both classical and alternative complement pathways (6,7). There are also reported cases of acquired lipodystrophy among individuals who have undergone haematopoietic stem cell transplantation (8). The study of humans affected by lipodystrophy syndromes demonstrates the essential role of white adipose tissue for the efficient storage of excess dietary energy. Under conditions where calories are plentiful healthy adipose tissue depots will expand to accommodate the excess energy in the form of triglyceride within unilocular lipid droplets (9). Adipose expandability is impaired in lipodystrophy due to the varying degrees of functional adipose tissue deficiency. The consequences of this impaired adipose expandability are striking, where excess energy is not sufficiently sequestered in adipose depots it will be diverted to ectopic sites such as liver, muscle and pancreas leading to insulin resistance, altered glucose homeostasis, polycystic ovarian syndrome, non-alcoholic fatty liver disease (NAFLD) and dyslipidaemia (9,10). Recombinant leptin therapy (metreleptin, Myalept) is the only licensed pharmacotherapy in the specific management of the lipodystrophy associated complications arising due to the hypoleptinaemia of lipodystrophy (1). However, the mainstay of treatment in all lipodystrophy patients at risk of metabolic complications is reduced fat/calorie intake to reduce the burden of ectopic lipid in addition to the management of specific complications as they arise. 

In this review we will discuss recent developments in the field of lipodystrophy highlighting research relating to the diagnosis and/or management of lipodystrophy subtypes in addition to the insights that have been gained into human physiology where lipodystrophy syndromes have been used as a model of disease.


Nonsense mutations in PLIN1 are not associated with an overt lipodystrophy phenotype
Perilipin 1 (PLIN1) is a largely adipocyte specific lipid droplet protein that regulates triglyceride storage by exerting control over basal and stimulated lipolysis (11). A number of heterozygous frameshift mutations in the PLIN1 gene that impaired the inhibition of basal lipolysis in vitro have been associated with a rare subtype of familial partial lipodystrophy (FPLD4)(12,13). Kozusko et al identified a frameshift mutation PLIN1 p.439fs where it was less clear how the mutant protein would affect lipolysis, so the authors hypothesized that reduced expression of the protein, coupled with increased expression of PLIN2 might contribute to altered lipolytic regulation in vivo (13). In support of this observation a 20% reduction in adipose mass was observed in PLIN1 heterozygous knockout mice when compared to PLIN1 homozygous knockout mice although the difference was not statistically significant (14). More recently, Laver and colleagues selected individuals with heterozygous null mutations (nonsense or frameshift) in PLIN1 predicted, though not confirmed experimentally, to cause haploinsufficiency from a cohort of 2208 individuals who had PLIN1 sequenced as part of a Next Generation Sequencing panel (15). Participants were referred for genetic testing based on a clinical suspicion of maturity onset diabetes of the young (MODY), hyperinsulinaemic hypoglycaemia or neonatal diabetes. Six individuals were identified within this cohort as having a heterozygous null variant none of which had hypertriglyceridaemia or were reported to have clinically apparent lipodystrophy from available clinical information, though detailed phenotyping was not performed in many of these cases. The hypothesis that mutations predicted to result in haploinsufficiency for PLIN1 are not associated with a lipodystrophy phenotype was tested in a large independent cohort where whole exome sequencing had been undertaken.  Among 14 individuals who were heterozygous for PLIN1 “null” variants neither hyperinsulinaemia nor dyslipidaemia were observed.  Together these observations suggest that haploinsufficiency for PLIN1 is not associated with an overt lipodystrophy phenotype (15). These findings have implications when attributing pathogenicity to heterozygous “null” PLIN1 variants that are identified incidentally or in the setting of a lipodystrophy diagnostic panel. Nevertheless, it may be that haploinsufficiency of PLIN1 in humans is not entirely benign and represents an intermediate phenotype as was suggested by the mouse model of haploinsufficiency, in which case rigorous phenotyping of PLIN1 null variant carriers in an appropriately powered study may address this uncertainty. Of course, if it is the case that haploinsufficiency is truly benign then it raises interesting mechanistic questions on how mutant Perilipin 1 mediates a lipodystrophy phenotype in a seemingly dominant-negative fashion.


Adipose tissue phenotype presents before puberty in children with LMNA mutations (FPLD2)
The identification of probands affected by lipodystrophy syndromes allows for predictive screening in offspring and relatives. The longitudinal study of pre-symptomatic individuals identified in this manner can provide valuable insights into the natural history of rare diseases. In the case of familial partial lipodystrophy type 2 (FPLD2) which arises due to mutations in LMNA, anecdotal evidence suggested that the adipose phenotype developed at the time of puberty (2,16). However, this had not been systematically studied. Recently, Patni and colleagues characterised the changes in body fat and metabolic parameters in 46 children who had a genetic diagnosis of FPLD2 based on “typical” pathogenic LMNA mutations ie. variants previously associated with an FPLD2 phenotype (17).  They retrospectively reviewed assessments of skin fold thickness at different sites as a measure of body fat and compared these measures to an age and gender matched control group from the NHANES study (18). The majority of the female participants with “typical” LMNA mutations had tricep skinfold thickness below the 25th percentile of NHANES controls. A number of these children were pre-pubertal at the time of assessment demonstrating that the adipose tissue loss developed before the onset of puberty. Interestingly among the male participants measures of tricep skinfold thickness ranged from the 1st to 75th centile of the NHANES controls group (17). Hypertriglyceridaemia affects many individuals affected by lipodystrophic syndromes, as such Patni et al assessed triglyceride (TG) levels in the paediatric LMNA cohort as a marker of the development of metabolic complications of the condition.   TG levels were significantly increased in the affected female cohorts aged 7- 12 years and 13-18 years when compared to matched controls, while in the latter group HDL cholesterol levels were also significantly reduced. Among male participants significant metabolic differences were not noted until adulthood (18 years) (17). These observations provide objective evidence that the adipose phenotype associated with “typical” LMNA mutations can develop before the onset of puberty. It also raises interesting questions regarding gender specific differences in the presentation and severity of this condition, however further appropriately powered studies are required to confirm the gender differences. 


The use of structural and functional characterisation of PPAR gamma to inform management decisions.
Familial partial lipodystrophy type 3 (FPLD3) is a monogenic disorder that arises due to pathogenic mutations of the nuclear receptor PPAR gamma (19). Synthetic agonists of the receptor, thiazolidinediones (TZD) are approved for use in the treatment of type 2 diabetes mellitus (20,21). Interestingly the limited experience of TZD use in individuals affected by FPLD3, has demonstrated variable efficacy (22,23). Agostini et al hypothesised that different mutations in the ligand binding domain of PPAR gamma could exert a differential effect on the binding of natural (endogenous) and synthetic ligands and this may underpin the responsiveness of certain patients with FPLD3 to TZDs (24). The hypothesis is well founded based on observations from the work of Maijithia et al during the prospective in vitro functional classification of all PPARG missense variants where some displayed divergent transcriptional responses to endogenous and synthetic ligands (25). To examine this further Agostini et al studied one established (p.R308P) and one novel (p.A261E) pathogenic PPARG mutation known to cause FPLD3, demonstrating in vitro that both variants had a greater transcriptional response to the synthetic ligands pioglitazone, rosiglitazone and falglitazar than to a putative endogenous ligand prostaglandin J2 (PGJ2). Crystallographic modelling provided a structural basis for the assay findings. Importantly patients with FPLD3 carrying either mutation demonstrated a clinical response in metabolic parameters when treated with TZD’s providing evidence that this finding holds true in vivo (24). These observations suggest that the impaired transcriptional responsiveness to endogenous ligands may be responsible for the clinical phenotype of impaired adipogenesis. The ability for synthetic ligands to activate the receptor in individual mutations has important implications for treatment decisions in FPLD3 where pharmacological options are limited and focus mostly on managing the metabolic complications arising from the condition. In the emerging era of personalised medicine FPLD3 is a condition where pharmacogenetic approaches may be used to offer individualised therapy.


Leptin replacement therapy in lipodystrophy mediates metabolic benefits independent of its effects on food intake
Lipodystrophy also affects the endocrine function of adipocytes. Leptin is an adipokine that is made in and secreted by adipocytes into the systemic circulation where serves as a homeostatic regulator of adipose tissue mass through its activation of hypothalamic pathways involved in appetite regulation (26).  Among those affected by lipodystrophy low levels of endogenous leptin are seen, which correlates to the amount of functional adipose present (27). Metreleptin (Myalept) is a recombinant analogue of leptin. It has been shown to improve metabolic parameters in patients with generalised lipodystrophy and selected cases of partial lipodystrophy (28,29,30). Metreleptin (Myalept) is licenced for the treatment of generalised lipodystrophy in the United States while in Japan it is approved in both partial and generalised lipodystrophy (1). In the European Union it was authorised for use under the designation of an “orphan medicine” since 2012 and available on compassionate basis, however it received marketing authorisation from the European Medicines Agency in 2018. In Europe it is licenced as an adjunct to diet in the treatment of the complications of leptin deficiency in adults and children(>2 years) with congenital or acquired generalised lipodystrophy and for the management of metabolic complications of lipodystophy in adults and children (>12 years) with partial lipodystrophy (31).  Exogenous leptin therapy in hypoleptinaemic lipodystrophic patients reduces caloric intake and it is believed that this is the major factor contributing to the favourable metabolic effects of leptin replacement therapy in lipodystrophy (32,28). Brown et al challenged this dogma by studying the metabolic impact of recombinant leptin therapy in a cohort of lipodystrophic patients under conditions of an isocaloric clamp (33). Two distinct cohorts were studied, the first included lipodystrophic patients receiving recombinant leptin who underwent a withdrawal of treatment while the second group were hypoleptinaemic leptin naïve lipodystrophic patients, both cohorts were assessed while on and off metreleptin. Peripheral insulin sensitivity significantly increased in both groups while receiving metreleptin therapy compared to when they were not receiving metreleptin.  However, the initiation cohort demonstrated significant changes in other metabolic parameters including an increase in hepatic insulin sensitivity, reduced plasma and hepatic triglycerides and reduced fasting glucose levels, these effects that were not matched by the cohort stopping metreleptin (33). In this study it was observed that leptin replacement in the context of hypoleptinaemia of lipodystrophy had food independent metabolic benefits, thus providing human evidence that is reflective of findings from previous rodent studies (34). The lack of reciprocity in the leptin withdrawal groups is interesting and raised questions as to whether the metabolic milieu which differed between the groups may influence leptin physiology (33). The hypoleptinaemic state associated with lipodystrophy is a valuable model in which to study leptin physiology. In the context of other hypoleptinaemic states (eg. following weight loss) the physiological manifestations of leptin replacement do not mirror those which were demonstrated by Brown et al in the metreleptin administration group (35,36). Together these observations suggest that the actions of leptin in vivo may be dependent on the metabolic milieu.  Further work may determine a basis for these beneficial metabolic effects advancing our understanding of leptin biology.


Genetically determined gluteofemoral fat storage is associated with cardiometabolic risk factors in the general population
The significant overlap in metabolic complications and cardiometabolic risk between lipodystrophy and the metabolic syndrome has generated considerable interest into the possibility of a shared pathophysiology between the conditions (37). Specifically, there is interest in the role of gluteal and femoral adipose tissue expansion in sequestering lipid and protecting against cardiometabolic risk (38,39). To explore this, Lotta and colleagues undertook a genome wide association study (GWAS), they identified 53 genetic loci that associated with higher BMI corrected fasting insulin, triglycerides and lower HDL cholesterol. The SNP’s were used to generate an insulin resistance (IR) genetic risk score based on the presence of the lead SNP at each loci and were validated against gold standard measurements of insulin sensitivity. In a large phenotyped human cohort there was a significant association between higher IR SNP scores, lower levels of gynoid and leg fat mass and reduced expansion of this depot in response to weight gain as measured by DEXA (40). These findings provide evidence that the ability of gluteofemoral depots to expand and store excess dietary energy is in part genetically determined and may be relevant in the pathophysiology of metabolic disease in the general population (40). Waist-hip ratio is a widely used non-invasive measure of adipose tissue distribution and its relationship to diabetes and cardiometabolic risk is established (41,42). As a ratio WHR is determined by an increase in abdominal circumference or a reduction in hip circumference. Much emphasis has been placed in the causal contribution of expansion of abdominal adipose depots to cardiometabolic risk however observations from rare lipodystrophy syndromes and recent GWAS support the notion of impaired expansion of gluteofemoral depots is in itself a contributor to cardiometabolic risk (40,43). Lotta et al again explored the genetic determinants of adipose tissue distribution undertaking a GWAS of common genetic variants associated with increased WHR (44). 202 genetic variants associated with increased WHR were identified in participants of European ancestry recruited to the UK Biobank. These variants were used to generate a WHR polygenic risk scores that reflected the different determinants of WHR, variants specifically associated with increased abdominal fat distribution (36 variants) or specifically associated with reduced gluteofemoral fat distribution (22 variants) were selected for the respective scores. Both of the WHR polygenic scores associate with cardiometabolic risk factors and increased odds ratio of type 2 diabetes mellitus and coronary disease when applied to a cohort of 636,607 people. Interestingly, the hip specific WHR score was associated with increased fasting insulin levels and LDL cholesterol which was not true of the waist specific WHR. The findings suggest that distinct genetic mechanism may contribute to gluteofemoral and abdominal adipose depots and they independently influence cardiometabolic risk (44).  When considered in the context of previous studies the findings support the hypothesis that impairment of gluteofemoral adipose tissue lipid storage contributes to an increase in WHR and associates with a higher cardiometabolic risk in the general population, thus implicating impaired adipose tissue expandability in the pathogenesis of the metabolic syndrome. 

Conclusion
As with other rare diseases conducting research into lipodystrophy syndromes is challenging. However, we have seen that the increasing awareness and diagnosis of the condition can provide the critical mass needed for ongoing human research studies. Continued efforts to conduct research into specific subtypes of lipodystrophy is important for advancing our capabilities to correctly diagnose and treat those affected. We have also seen that rare syndromes of lipodystrophy can provide a valuable model in which to examine different aspects of adipose biology in humans, providing new insights into leptin physiology in humans as well driving hypotheses on the contribution of adipose expandability to metabolic disease in the general population.
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